Indeed, we found that tumour growth could be slowed by treatment with the EGFR-inhibitor sapitinib (AZD8931/EGFRi) specifically in VilCreER;Apcfl/+;KrasG12D/+;Alk5CA mice but not in VilCreER;Apcfl/+;KrasG12D/+ mice (Fig. 7d–f and Supplementary Fig. 7d). Here, EGFR is linked to neoplasm.